Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off
Close

Ginkgo Bioworks Holdings (DNA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Ginkgo Bioworks's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.530 +0.010    +0.66%
16:00:01 - Closed. Currency in USD ( Disclaimer )
After Hours
1.320
-0.210
-13.725%
18:09:02 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 30,627,609
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.440 - 1.610
Ginkgo Bioworks 1.530 +0.010 +0.66%

NYSE:DNA Financials

 
A brief overview of the NYSE:DNA financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Ginkgo Bioworks Holdings over time.

Ginkgo Bioworks Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 37.18 million compared to USD 24.68 million a year ago. Revenue was USD 55.43 million compared to USD 66.4 million a year ago. Net loss was USD 302.89 million compared to USD 670.13 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.41 a year ago.For the nine months, sales was USD 116.56 million compared to USD 90.41 million a year ago. Revenue was USD 216.7 million compared to USD 379.42 million a year ago. Net loss was USD 681.18 million compared to USD 1,929.46 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 1.19 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

DNA Income Statement

Gross margin TTM 75.36%
Operating margin TTM -249.13%
Net Profit margin TTM -271.96%
Return on Investment TTM -42.77%
 Total Revenue  Net Income
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Revenue 55.43 80.57 80.7 98.28
Gross Profit 48.51 62.47 58.33 68.07
Operating Income -172.22 -184.15 -215.74 -233.71
Net Income -302.89 -173.32 -204.97 -176.54

DNA Balance Sheet

Quick Ratio MRQ 6.6
Current Ratio MRQ 6.78
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 32.22%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Assets 2026.39 2292 2417.21 2539.32
Total Liabilities 773.71 788.41 809.62 803.04
Total Equity 1252.68 1503.58 1607.59 1736.28

DNA Cash Flow Statement

Cash Flow/Share TTM -0.16
Revenue/Share TTM 0.15
Operating Cash Flow  -43.66%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -73.55 -73.53 -90.58 -104.7
Cash From Investing Activities -3.38 -11.22 -19.41 29.74
Cash From Financing Activities -0.315 -1.38 -0.888 97.93
Net Change in Cash -77.44 -86.61 -110.91 24.07
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DNA Comments

Write your thoughts about Ginkgo Bioworks Holdings
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Marshall Green
Marshall Green Feb 23, 2024 3:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Congressional committee visits new buildings. Kicking the tires before they invest?
TechTrend Trades
TechTrend Trades Nov 09, 2023 2:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wait until Q1 2024. Healthcare is not a buy right now
Jack Jack
Jack Jack Nov 08, 2023 6:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Cathy Woods is looser
TechTrend Trades
TechTrend Trades Nov 08, 2023 6:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
yup
Jeremy Glaser
Jeremy Glaser Nov 07, 2023 12:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sell sell it's 4 cents up
Dharmik Prajapati
Dharmik Prajapati Oct 27, 2023 10:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$1.00 can take place in coming days too due to all over the world markets are going down
Jeremy Glaser
Jeremy Glaser Oct 27, 2023 10:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
don't think that's gonna happen probably going to 🚀 up instead
Dharmik Prajapati
Dharmik Prajapati Oct 27, 2023 10:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$1.07 will be the price point in coming days
peter pan
peter pan Aug 31, 2023 5:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
DNA may hit 4 next week!
peter pan
peter pan Aug 30, 2023 12:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I think DNA will go to $9 in next 2 months. just like JOBY.
Dharmik Prajapati
Dharmik Prajapati Aug 30, 2023 12:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Be careful
Dan Thomas
Dan Thomas Aug 29, 2023 8:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
haha, up on news that dna will uses a cloud.
peter pan
peter pan Aug 29, 2023 8:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it is time for DNA to go to $5. hope to hear some big news.
Dharmik Prajapati
Dharmik Prajapati Aug 29, 2023 8:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
After big fall coming soon around $1.00 and it will take year or years to $5 or more. / may be if everything goes right $10
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email